297 related articles for article (PubMed ID: 32472441)
21. Reclassifying endometrial carcinomas with a combined morphological and molecular approach.
Carlson J; McCluggage WG
Curr Opin Oncol; 2019 Sep; 31(5):411-419. PubMed ID: 31261170
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer.
Raffone A; Travaglino A; Cerbone M; Gencarelli A; Mollo A; Insabato L; Zullo F
Pathol Oncol Res; 2020 Jul; 26(3):1417-1427. PubMed ID: 32377987
[TBL] [Abstract][Full Text] [Related]
23. Molecular insights into the classification of high-grade endometrial carcinoma.
Hussein YR; Soslow RA
Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451
[TBL] [Abstract][Full Text] [Related]
24. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
Raffone A; Travaglino A; Raimondo D; Maletta M; De Vivo V; Visiello U; Casadio P; Seracchioli R; Zullo F; Insabato L; Mollo A
Int J Gynaecol Obstet; 2022 Sep; 158(3):520-527. PubMed ID: 34797919
[TBL] [Abstract][Full Text] [Related]
25. Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics.
Liwei L; He L; Yibo D; Luyang Z; Zhihui S; Nan K; Danhua S; Junzhu W; Zhiqi W; Jianliu W
World J Surg Oncol; 2023 Oct; 21(1):332. PubMed ID: 37865800
[TBL] [Abstract][Full Text] [Related]
26. Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel.
López-Reig R; Fernández-Serra A; Romero I; Zorrero C; Illueca C; García-Casado Z; Poveda A; López-Guerrero JA
Sci Rep; 2019 Dec; 9(1):18093. PubMed ID: 31792358
[TBL] [Abstract][Full Text] [Related]
27. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
28. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
29. Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common
Kitazono I; Akahane T; Kobayashi Y; Yanazume S; Tabata K; Tasaki T; Noguchi H; Kirishima M; Higashi M; Kobayashi H; Tanimoto A
Int J Surg Pathol; 2022 Dec; 30(8):891-899. PubMed ID: 35360975
[No Abstract] [Full Text] [Related]
30. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
32. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M; Hui P
Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
[TBL] [Abstract][Full Text] [Related]
33. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
34. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
35. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Espinosa I; D'Angelo E; Prat J
Gynecol Oncol; 2024 Apr; 186():94-103. PubMed ID: 38615479
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
[TBL] [Abstract][Full Text] [Related]
37. Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
Li J; Xing X; Li D; Zhang B; Mutch DG; Hagemann IS; Wang T
Neoplasia; 2017 Feb; 19(2):100-111. PubMed ID: 28088687
[TBL] [Abstract][Full Text] [Related]
38. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
Abdulfatah E; Wakeling E; Sakr S; Al-Obaidy K; Bandyopadhyay S; Morris R; Feldman G; Ali-Fehmi R
Gynecol Oncol; 2019 Sep; 154(3):467-474. PubMed ID: 31248668
[TBL] [Abstract][Full Text] [Related]
39. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.
Santoro A; Angelico G; Travaglino A; Inzani F; Arciuolo D; Valente M; D'Alessandris N; Scaglione G; Fiorentino V; Raffone A; Zannoni GF
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073635
[TBL] [Abstract][Full Text] [Related]
40. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
